Today: 28 June 2026
Browse Category

NYSE:CTLT 27 June 2025

Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

The FDA approved Abeona’s Zevaskyn, the first cell-based gene therapy for RDEB, in April 2025, with launch set for Q3 at $3.1 million. Vertex’s CRISPR therapy Casgevy generated $2 million in Q3 2024. Novo Holdings acquired Catalent for $16.5 billion in January 2025 to secure GLP-1 drug manufacturing. Johnson & Johnson bought Intra-Cellular Therapies for $14.6 billion, expanding its neuroscience portfolio.
27 June 2025
···········

Stock Market Today

  • Goldman Sachs Shares Pull Back 7% After 50% Annual Gain; Valuation Seen Slightly Overvalued
    June 28, 2026, 4:22 AM EDT. Goldman Sachs (GS) shares closed at $1,019.61 on June 28, down 7% over the past week but up 50.6% over the last year. Despite a strong three-year gain of 239.1%, the stock showed a recent pullback. Valuation analysis using an Excess Returns model indicates the stock is about 10.4% overvalued, with an intrinsic value estimated at $923.45 versus the current price. Investors are advised to carefully consider Price-to-Earnings (P/E) ratios and valuation models amid robust long-term gains and evolving market conditions before making new investment decisions.

Latest articles

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 28.06.2026

28 June 2026
LIVEMarkets rolling coverageStarted: June 28, 2026, 4:00 AM EDTUpdated: June 28, 2026, 4:26 AM EDT Goldman Sachs Shares Pull Back 7% After 50% Annual Gain; Valuation Seen Slightly Overvalued June 28, 2026, 4:22 AM EDT. Goldman Sachs (GS) shares closed at $1,019.61 on June 28, down 7% over the past week but up 50.6% over the last year. Despite a strong three-year gain of 239.1%, the stock showed a recent pullback. Valuation analysis using an Excess Returns model indicates the stock is about 10.4% overvalued, with an intrinsic value estimated at $923.45 versus the current price. Investors are advised to
Go toTop